

Question Paper

Exam Date & Time: 10-Apr-2023 (10:00 AM - 01:00 PM)



MANIPAL ACADEMY OF HIGHER EDUCATION

Answer ALL questions.

Clinical Research [PPR 5.1T-S2]

Marks: 70

Duration: 180 mins.

Section A

Answer all the questions.

Long Answer Questions (3 x 10 marks = 30 marks)

- | | | |
|----|---|------|
| 1) | Define investigational new drug application (IND). Explain the IND submission and processes | (10) |
| 2) | Prepare a case report form (CRF) for a research protocol of myocardial infraction with dyslipidaemia as a comorbidity | (10) |
| 3) | Describe periodical safety monitoring report in clinical research | (10) |

Section B

Answer all the questions.

Short Answer Questions (6 x 5 marks = 30 marks)

- | | | |
|----|---|-----|
| 4) | Discuss the advantages and disadvantages of Phase 4 in clinical trials | (5) |
| 5) | Explain the duties of responsibilities of CDSCO | (5) |
| 6) | Differentiate the roles and responsibilities of auditor and monitor in clinical research | (5) |
| 7) | List the vulnerable populations and explain the informed consent process for pregnant women | (5) |
| 8) | What are various dosage form in which a new drug can be developed? | (5) |
| 9) | Explain the record keeping and archiving of clinical research/trial data | (5) |

Section C

Answer all the questions.

Give Reasons for the Following (5 x 2 marks = 10 marks)

- | | | |
|-----|---|-----|
| 10) | Phase 2 clinical trial has two sections | (2) |
| 11) | Waiver of consent from institutional ethical committee (IEC) | (2) |
| 12) | The regulatory authorities realizing the importance of applying appropriate measures to stifle the increasing incidences of adverse reactions | (2) |
| 13) | CTRI registration is required for clinical trials | (2) |
| 14) | An abbreviated new drug application contains data which is submitted to FDA for the review | (2) |

-----End-----